cedazuridine: Clinical Trials

13 trials of cedazuridine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 active not recruiting, 2 terminated, 1 recruiting. 13 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 5, Active not recruiting 4, Terminated 2, Recruiting 1, Withdrawn 1
Phase 27Completed 3, Active not recruiting 2, Terminated 2

Follow cedazuridine: new trials by email Literature Review of cedazuridine trials Research Report on cedazuridine

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
INQOVI (decitabine and cedazuridine), Nivolumab - Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma
Phase 1WithdrawnCase Comprehensive Cancer Center2024-06-012024-07-03
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)32023-11-142025-12-02
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine - Myelodysplastic Syndromes
Phase 1 / Phase 2Active not recruitingOtsuka Beijing Research Institute722023-10-162026-10-16
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Defactinib - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1RecruitingClinical Hub for Interventional Research (CHOIR)122022-12-142026-03-18
BMS-986253 in Myelodysplastic Syndromes
Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)22022-11-292025-09-30
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab - Malignant Melanoma
Phase 1 / Phase 2CompletedUniversity of Colorado, Denver82022-06-202026-11-09
Inqovi Maintenance Therapy in Myeloid Neoplasms
Inqovi - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1Active not recruitingMassachusetts General Hospital222021-09-172026-03-30
Thorough QT Assessment of Cedazuridine in Healthy Subjects
Cedazuridine, Placebo, Moxifloxacin - Healthy Volunteers
Phase 1CompletedAstex Pharmaceuticals, Inc.362021-07-012024-08-02
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Decitabine and Cedazuridine (ASTX727), Venetoclax - Acute Myeloid Leukemia
Phase 1 / Phase 2Active not recruitingTaiho Oncology, Inc.1012021-02-092026-10-06
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Decitabine, Cedazuridine - Solid Tumor
Phase 1Active not recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins352019-04-172026-09-08
Effect of Food on Blood Levels of ASTX727
ASTX727 + Day 2 Food, ASTX727 + Day 4 Food - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1CompletedAstex Pharmaceuticals, Inc.182018-11-082024-08-02
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
ASTX727 LD, ASTX727 SD - Myelodysplastic Syndromes
Phase 1 / Phase 2CompletedTaiho Oncology, Inc.1602018-07-272026-04-03
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination - Myelodysplastic Syndrome, MDS
Phase 1 / Phase 2CompletedAstex Pharmaceuticals, Inc.1302014-10-282024-08-27

Conditions studied

Myelodysplastic Syndromes (8)  ·  Leukemia, Myeloid, Acute (4)  ·  Leukemia, Myelomonocytic, Chronic (3)  ·  Carcinoma, Squamous Cell (1)  ·  Cytopenia (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Melanoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Astex Pharmaceuticals, Inc. (3)  ·  National Cancer Institute (NCI) (2)  ·  Taiho Oncology, Inc. (2)  ·  Case Comprehensive Cancer Center (1)  ·  Clinical Hub for Interventional Research (CHOIR) (1)  ·  Massachusetts General Hospital (1)  ·  Otsuka Beijing Research Institute (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  University of Colorado, Denver (1)

Countries

United States (10)  ·  Canada (3)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  China (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)

Top investigators

Najla El Jurdi, M.D. (2)  ·  James Lowder, MD (1)  ·  John Pimanda, Professor (1)  ·  Kyunghee Burkitt, DO, PhD (1)  ·  Martin McCarter (1)  ·  Mohammad Azab, MD (1)  ·  Nilofer Azad, MD (1)  ·  Zachariah DeFilipp, MD (1)

Results publications

PMID 30926081, PMID 32285126, PMID 42235013